MX377729B - Métodos para tratamiento del melanoma. - Google Patents

Métodos para tratamiento del melanoma.

Info

Publication number
MX377729B
MX377729B MX2015010312A MX2015010312A MX377729B MX 377729 B MX377729 B MX 377729B MX 2015010312 A MX2015010312 A MX 2015010312A MX 2015010312 A MX2015010312 A MX 2015010312A MX 377729 B MX377729 B MX 377729B
Authority
MX
Mexico
Prior art keywords
methods
treating melanoma
melanoma
treating
taxane
Prior art date
Application number
MX2015010312A
Other languages
English (en)
Spanish (es)
Other versions
MX2015010312A (es
Inventor
Markus Renschler
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/791,841 external-priority patent/US9149455B2/en
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2015010312A publication Critical patent/MX2015010312A/es
Publication of MX377729B publication Critical patent/MX377729B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
MX2015010312A 2013-02-11 2013-12-03 Métodos para tratamiento del melanoma. MX377729B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763391P 2013-02-11 2013-02-11
US13/791,841 US9149455B2 (en) 2012-11-09 2013-03-08 Methods of treating melanoma
PCT/US2013/072877 WO2014123612A1 (en) 2013-02-11 2013-12-03 Methods of treating melanoma

Publications (2)

Publication Number Publication Date
MX2015010312A MX2015010312A (es) 2015-11-18
MX377729B true MX377729B (es) 2025-03-11

Family

ID=51300036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010312A MX377729B (es) 2013-02-11 2013-12-03 Métodos para tratamiento del melanoma.

Country Status (13)

Country Link
EP (1) EP2953622B1 (cg-RX-API-DMAC7.html)
JP (3) JP6388880B2 (cg-RX-API-DMAC7.html)
KR (1) KR102148551B1 (cg-RX-API-DMAC7.html)
CN (2) CN109200031A (cg-RX-API-DMAC7.html)
BR (1) BR112015019064A8 (cg-RX-API-DMAC7.html)
CA (1) CA2900668A1 (cg-RX-API-DMAC7.html)
ES (1) ES2872328T3 (cg-RX-API-DMAC7.html)
HK (1) HK1218506A1 (cg-RX-API-DMAC7.html)
IL (1) IL240388B (cg-RX-API-DMAC7.html)
MX (1) MX377729B (cg-RX-API-DMAC7.html)
NZ (1) NZ630239A (cg-RX-API-DMAC7.html)
WO (1) WO2014123612A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505956B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN113599534A (zh) * 2014-10-06 2021-11-05 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
CN114796130B (zh) * 2015-08-18 2023-10-20 梅约医学教育与研究基金会 载体结合剂组合物及其制备和使用方法
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
KR102462041B1 (ko) * 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2301531T1 (sl) * 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2620389C (en) 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
NZ593343A (en) * 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2012048223A1 (en) * 2010-10-08 2012-04-12 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer

Also Published As

Publication number Publication date
WO2014123612A1 (en) 2014-08-14
JP6388880B2 (ja) 2018-09-12
JP2019056014A (ja) 2019-04-11
EP2953622A4 (en) 2016-09-21
NZ630239A (en) 2017-08-25
EP2953622A1 (en) 2015-12-16
KR20150119177A (ko) 2015-10-23
BR112015019064A8 (pt) 2019-11-12
CN105120859B (zh) 2018-10-09
ES2872328T3 (es) 2021-11-02
KR102148551B1 (ko) 2020-08-26
BR112015019064A2 (pt) 2017-07-18
EP2953622B1 (en) 2021-03-24
MX2015010312A (es) 2015-11-18
JP2016513097A (ja) 2016-05-12
ZA201505956B (en) 2016-11-30
CA2900668A1 (en) 2014-08-14
IL240388A0 (en) 2015-09-24
IL240388B (en) 2020-07-30
HK1218506A1 (zh) 2017-02-24
CN105120859A (zh) 2015-12-02
CN109200031A (zh) 2019-01-15
JP2018016660A (ja) 2018-02-01
JP6470381B2 (ja) 2019-02-13

Similar Documents

Publication Publication Date Title
MX377729B (es) Métodos para tratamiento del melanoma.
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
HK1216853A1 (zh) 治療胰腺癌的方法
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
PH12015500525A1 (en) Formulations of enzalutamide
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
MY168032A (en) Warm-Cool Beauty Treatment Device
ZA201602380B (en) Cancer treatment with combination of plinabulin and taxane
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
HK1216083A1 (zh) 经动脉的药物递送
UA117663C2 (uk) Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
AU350280S (en) Apparatus for skin treatment
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3747907A3 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
MX2015013021A (es) 5-bromo-indirrubinas.
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
EA201690445A1 (ru) Лечение рака
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
PH12015500468B1 (en) Treatment and prevention of acne

Legal Events

Date Code Title Description
FG Grant or registration